2024年1月9日,中国上海——卫材(中国)药业有限公司宣布抗阿尔茨海默症药物乐意保(Leqembi)®(仑卡奈单抗Lecanemab)获国家药品监督管理局(NMPA)批准正式进入中国。
发布时间:2024-01-09浏览数:514
AL001是由美国南佛罗里达大学(University of South Florida)的Douglas Ronald Shytle和Jun Tan合作开发的用于治疗阿尔茨海默症(AD)的水杨酸锂L-脯氨酸共晶(LISPRO),已完成治疗AD的2a期临床…
发布时间:2023-10-02浏览数:521
2023年7月17日Eli Lilly公布了抗β淀粉样蛋白(Aβ)单克隆抗体Donanemab的3期临床试验TRAILBLAZER-ALZ 2试验结果。试验显示 Donanemab能够有效改善Aβ斑块检测阳性阿尔茨海默症早期症状患者的认…
发布时间:2023-07-17浏览数:864
Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium t…
发布时间:2023-07-17浏览数:673
In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76…
发布时间:2021-05-06浏览数:554
Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.
发布时间:2021-02-14浏览数:657
These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease.
发布时间:2012-01-06浏览数:645
A beta N3(pE) production and retention may play an early and critical role in senile plaque formation.
发布时间:1995-02-01浏览数:568
横切线®为注册商标
Copyright 2020 横切线®药研苑 备案号:粤ICP备18041379号-3